

Consensus molecular subtypes and the evolution of pre-cancer

Nature Reviews Cancer

17, 79-92

DOI: [10.1038/nrc.2016.126](https://doi.org/10.1038/nrc.2016.126)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. <i>Oncolmmunology</i> , 2017, 6, e1284720.	2.1	18
3	Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1228-1236.	1.2	30
4	Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 54-60.	3.4	99
5	Early detection: the impact of genomics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 165-173.	1.4	10
6	Genetic and epigenetic markers in colorectal cancer screening: recent advances. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 665-685.	1.5	22
7	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.4	116
9	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1046-1055.	1.6	42
10	Precision Oncology: The Road Ahead. <i>Trends in Molecular Medicine</i> , 2017, 23, 874-898.	3.5	131
11	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
12	Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	11
13	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. <i>Scientific Reports</i> , 2017, 7, 16618.	1.6	229
15	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-1 (CD274) expression: Possible roles of tumour micro environmental factors for CD274 expression. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 268-278.	1.3	18
16	Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. <i>Annals of Oncology</i> , 2017, 28, 2160-2168.	0.6	41
17	In Defense of Flossing: Part II-Can We Agree It's Premature to Claim Flossing Is Ineffective to Help Prevent Periodontal Diseases?. <i>Journal of Evidence-based Dental Practice</i> , 2017, 17, 149-158.	0.7	7
18	Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. <i>Clinical Epigenetics</i> , 2017, 9, 55.	1.8	35
19	Antiangiogenic therapies in colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 213-217.	0.3	3
20	Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer. <i>Nutrients</i> , 2017, 9, 1076.	1.7	37
21	Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 890.	1.8	33

#	ARTICLE	IF	CITATIONS
22	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
23	Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737. <i>General Physiology and Biophysics</i> , 2017, 36, 539-547.	0.4	8
24	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
25	Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 232-245.	1.8	10
27	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	7.7	367
28	Quantification of Functional Heterogeneities in Tumors by PET Imaging. , 2018, , 395-410.		0
29	Engineering chimeric antigen receptor-T cells for cancer treatment. <i>Molecular Cancer</i> , 2018, 17, 32.	7.9	57
30	Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing. <i>Clinical Cancer Research</i> , 2018, 24, 2092-2099.	3.2	22
31	A Systems Approach to Refine Disease Taxonomy by Integrating Phenotypic and Molecular Networks. <i>EBioMedicine</i> , 2018, 31, 79-91.	2.7	60
32	Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 106-115.	1.2	5
33	Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?. <i>Journal of Surgical Oncology</i> , 2018, 117, 858-863.	0.8	20
34	MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. <i>Human Pathology</i> , 2018, 77, 108-115.	1.1	18
35	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 69-77.	2.0	17
36	Inhibition of <sc>DDR</sc> 1â€•<sc>BCR</sc> signalling by nilotinib asÂa new therapeutic strategy for metastatic colorectal cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	82
37	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
38	Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. <i>Gut</i> , 2018, 67, 1168-1180.	6.1	139
39	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. <i>Cancer Letters</i> , 2018, 419, 84-95.	3.2	52
40	Network science in clinical trials: A patient-centered approach. <i>Seminars in Cancer Biology</i> , 2018, 52, 135-150.	4.3	9

#	ARTICLE	IF	CITATIONS
41	DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 214-221.	1.5	7
42	Proteome Heterogeneity in Colorectal Cancer. <i>Proteomics</i> , 2018, 18, 1700169.	1.3	13
43	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. <i>Cell Death and Differentiation</i> , 2018, 25, 616-633.	5.0	137
44	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers. <i>European Journal of Human Genetics</i> , 2018, 26, 382-386.	1.4	11
45	Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. <i>Future Science OA</i> , 2018, 4, FSO306.	0.9	26
46	Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. <i>Nature Communications</i> , 2018, 9, 1793.	5.8	188
47	Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. <i>Clinical Epigenetics</i> , 2018, 10, 35.	1.8	38
48	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	7.7	396
49	CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. <i>Cell Death and Disease</i> , 2018, 9, 417.	2.7	497
50	Phosphorylation of p70 Ribosomal Protein S6 Kinase $\hat{2}$ -1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e331-e352.	1.0	13
51	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 807-820.	3.2	23
52	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 981-988.	2.0	89
53	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. <i>Clinical Cancer Research</i> , 2018, 24, 794-806.	3.2	177
54	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 231-238.	1.8	46
55	Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. , 2018, , .		6
56	Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer. <i>Current Drug Targets</i> , 2018, 19, 1731-1737.	1.0	12
57	The prognostic efficacy of cell-free DNA hypermethylation in colorectal cancer. <i>Oncotarget</i> , 2018, 9, 7010-7022.	0.8	13
58	Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. <i>British Journal of Cancer</i> , 2018, 119, 1367-1373.	2.9	30

#	ARTICLE	IF	CITATIONS
59	Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7155-7168.	1.0	7
60	Targeted Therapy of Colorectal Cancer Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
61	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 75-100.	0.8	7
62	Survival marker genes of colorectal cancer derived from consistent transcriptomic profiling. <i>BMC Genomics</i> , 2018, 19, 857.	1.2	48
63	Hypermethylation of DMTN promotes the metastasis of colorectal cancer cells by regulating the actin cytoskeleton through Rac1 signaling activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 299.	3.5	32
64	Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. <i>PLoS ONE</i> , 2018, 13, e0208547.	1.1	11
65	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. <i>Cancer Management and Research</i> , 2018, Volume 10, 5895-5908.	0.9	18
66	Linc00472 suppresses proliferation and promotes apoptosis through elevating PDCD4 expression by sponging miR-196a in colorectal cancer. <i>Aging</i> , 2018, 10, 1523-1533.	1.4	37
67	A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. <i>Cancers</i> , 2018, 10, 355.	1.7	22
68	Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data. <i>EBioMedicine</i> , 2018, 36, 183-195.	2.7	123
69	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	5.8	55
70	Genome-Wide Network-Based Analysis of Colorectal Cancer Identifies Novel Prognostic Factors and an Integrative Prognostic Index. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 1703-1716.	1.1	52
71	Prognostic Values of EPDR1 Hypermethylation and Its Inhibitory Function on Tumor Invasion in Colorectal Cancer. <i>Cancers</i> , 2018, 10, 393.	1.7	21
72	Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1. <i>Gastroenterology</i> , 2018, 155, 1868-1882.	0.6	39
73	CTHRC1 overexpression predicts poor survival and enhances epithelial-mesenchymal transition in colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5643-5654.	1.3	42
74	Quantitative assessment of cell population diversity in single-cell landscapes. <i>PLoS Biology</i> , 2018, 16, e2006687.	2.6	40
75	Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. <i>PLoS ONE</i> , 2018, 13, e0203051.	1.1	35
76	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 138-151.	1.0	0

#	ARTICLE	IF	CITATIONS
77	Sepsis: Personalized Medicine Utilizing "Omic"™ Technologies" A Paradigm Shift?. Healthcare (Switzerland), 2018, 6, 111.	1.0	20
78	SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer. Cellular Physiology and Biochemistry, 2018, 49, 463-478.	1.1	38
81	Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer. Cancer and Metastasis Reviews, 2018, 37, 545-555.	2.7	64
82	Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer. Oncology Letters, 2018, 15, 4207-4214.	0.8	5
83	Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer. International Journal of Colorectal Disease, 2018, 33, 995-1000.	1.0	5
84	Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. Advanced Science, 2018, 5, 1800614.	5.6	52
85	Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomedicine and Pharmacotherapy, 2018, 106, 1607-1615.	2.5	62
86	An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients. Cancer Management and Research, 2018, Volume 10, 1597-1604.	0.9	18
87	Teaming Up for Trouble: Cancer Cells, Transforming Growth Factor- β 21 Signaling and the Epigenetic Corruption of Stromal Na ⁺ ve Fibroblasts. Cancers, 2018, 10, 61.	1.7	30
88	Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PLoS ONE, 2018, 13, e0200163.	1.1	6
89	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
90	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treatment Reviews, 2018, 70, 1-8.	3.4	116
91	MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway. Cell Death and Disease, 2018, 9, 438.	2.7	78
93	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 2298.	1.8	4
94	Cancer of Other Origin. , 2018, , 283-291.		0
95	Cancer of Other Origin. , 2018, , 119-167.		0
96	Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review. Digestive Surgery, 2019, 36, 273-280.	0.6	10
97	Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 83-103.	9.6	169

#	ARTICLE	IF	CITATIONS
98	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 841-847.	2.3	26
99	The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer. <i>Cells</i> , 2019, 8, 929.	1.8	28
100	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	2.7	24
101	Immune Resistance and EGFR Antagonists in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1089.	1.7	37
102	<i>Fusobacterium</i> nucleatum-positive colorectal cancer (Review). <i>Oncology Letters</i> , 2019, 18, 975-982.	0.8	20
103	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. <i>Theranostics</i> , 2019, 9, 3485-3500.	4.6	9
104	Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. <i>BMC Cancer</i> , 2019, 19, 687.	1.1	15
105	Subtyping of microsatellite instability-high colorectal cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 79.	2.7	42
106	Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. <i>Cancers</i> , 2019, 11, 983.	1.7	14
107	Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers. <i>Scientific Reports</i> , 2019, 9, 10516.	1.6	17
108	Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. <i>Annals of Oncology</i> , 2019, 30, 1409-1410.	0.6	0
109	Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1042.	1.7	23
110	Intestinal PPAR α Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6. <i>Gastroenterology</i> , 2019, 157, 744-759.e4.	0.6	111
111	Oncogenic Pathways and Loss of the Rab11 GTPase Synergize To Alter Metabolism in <i>Drosophila</i> . <i>Genetics</i> , 2019, 212, 1227-1239.	1.2	12
112	Visualization of epithelial-mesenchymal transition in an inflammatory microenvironmentâ€“colorectal cancer network. <i>Scientific Reports</i> , 2019, 9, 16378.	1.6	29
113	Functional Prediction of Candidate MicroRNAs for CRC Management Using in Silico Approach. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5190.	1.8	6
114	The global challenge of colorectal cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 894-895.	3.7	65
115	TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells. <i>Molecular Oncology</i> , 2019, 13, 2393-2405.	2.1	32

#	ARTICLE	IF	CITATIONS
116	Advances in Molecular Subclassification of Colorectal Cancer. , 2019, , .		0
117	Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study. PLoS ONE, 2019, 14, e0221444.	1.1	1
118	Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?. Annals of Oncology, 2019, 30, 1538-1540.	0.6	4
119	Cetuximab, irinotecan and fluorouracile in first-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. BMC Cancer, 2019, 19, 899.	1.1	10
120	Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features. World Journal of Surgery, 2019, 43, 3207-3215.	0.8	2
121	Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer Cell, 2019, 36, 319-336.e7.	7.7	278
122	Back to the Colorectal Cancer Consensus Molecular Subtype Future. Current Gastroenterology Reports, 2019, 21, 5.	1.1	50
123	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. Histopathology, 2019, 75, 4-19.	1.6	8
124	JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 28.	3.5	24
125	Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 240-247.	3.3	81
126	Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p. American Journal of Physiology - Renal Physiology, 2019, 317, G222-G232.	1.6	57
127	Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers, 2019, 11, 859.	1.7	27
128	Prognostic Factors and Differences in Survival of Right and Left Colon Carcinoma: A STROBE Compliant Retrospective Cohort Study. Archives of Medical Research, 2019, 50, 63-70.	1.5	5
129	Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making. Journal of Clinical Oncology, 2019, 37, 1847-1850.	0.8	5
130	A Hybrid Neural Network Approach for Lung Cancer Classification with Gene Expression Dataset and Prior Biological Knowledge. Lecture Notes in Computer Science, 2019, , 279-293.	1.0	3
131	Network-based cancer precision medicine: A new emerging paradigm. Cancer Letters, 2019, 458, 39-45.	3.2	28
132	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Clinical Cancer Research, 2019, 25, 4431-4442.	3.2	40
133	Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. Visceral Medicine, 2019, 35, 124-132.	0.5	3

#	ARTICLE	IF	CITATIONS
134	Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 61-69.	1.0	27
135	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	1.6	38
136	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019, 111, 82-93.	1.3	17
137	KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 35, 559-572.e7.	7.7	353
138	<p></p>Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1337-1348.	0.9	39
139	The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 139.	1.6	76
140	Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. <i>PLoS Genetics</i> , 2019, 15, e1008076.	1.5	59
141	Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 65-82.	1.6	12
142	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
143	Differential genomic destabilisation in human cells with pathogenic MSH2 mutations introduced by genome editing. <i>Experimental Cell Research</i> , 2019, 377, 24-35.	1.2	12
144	Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. <i>Cancer Immunology Research</i> , 2019, 7, 701-706.	1.6	8
145	Radiogenomic Analysis of F-18-Fluorodeoxyglucose Positron Emission Tomography and Gene Expression Data Elucidates the Epidemiological Complexity of Colorectal Cancer Landscape. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 177-185.	1.9	51
147	Reduced RANBP9 expression is associated with poor prognosis in colorectal cancer patients. <i>Translational Cancer Research</i> , 2019, 8, 2704-2712.	0.4	1
148	Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer. <i>Medicine (United States)</i> , 2019, 98, e14781.	0.4	1
149	Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib. <i>Cancers</i> , 2019, 11, 1878.	1.7	13
151	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 73-73.	1.5	4
152	<p></p>Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 8543-8560.	3.3	50
153	Transforming Growth Factor- β 2 Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5822.	1.8	147

#	ARTICLE	IF	CITATIONS
154	Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 492.	3.5	28
155	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
156	New therapies and insights into the changing landscape of colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 79-80.	8.2	36
157	Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome. <i>Integrative Medicine Research</i> , 2019, 8, 21-25.	0.7	8
158	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3
159	Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors. , 2019, , 271-285.		1
160	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019, 72, 135-139.	1.0	28
161	Diagnostic and reporting issues of preneoplastic polyps of the large intestine with early carcinoma. <i>Annals of Diagnostic Pathology</i> , 2019, 39, 1-14.	0.6	12
162	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	2.1	70
163	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	2.9	29
164	CD44v6 engages in colorectal cancer progression. <i>Cell Death and Disease</i> , 2019, 10, 30.	2.7	85
165	LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. <i>Archives of Biochemistry and Biophysics</i> , 2019, 663, 183-191.	1.4	71
166	The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis. <i>Molecular Cancer</i> , 2019, 18, 5.	7.9	106
167	Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 5601-5612.	2.0	7
168	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55
169	NSAIDs and Colorectal Cancer Phenotypes: What Now?. <i>Journal of the National Cancer Institute</i> , 2019, 111, 440-441.	3.0	3
170	Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog mutant colorectal cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1106-1121.	1.2	0
171	Predictive Biomarkers and Targeted Therapies in Colorectal Cancer. , 2019, , 423-430.		2

#	ARTICLE	IF	CITATIONS
172	Mutant p53 in colon cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 267-276.	1.5	170
173	Progress in characterizing the linkage between <i>Fusobacterium nucleatum</i> and gastrointestinal cancer. <i>Journal of Gastroenterology</i> , 2019, 54, 33-41.	2.3	39
174	Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. <i>Translational Oncology</i> , 2019, 12, 76-83.	1.7	16
175	Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 378-389.	3.2	49
176	EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy. <i>Pathology and Oncology Research</i> , 2020, 26, 1429-1434.	0.9	7
177	A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease. <i>Translational Research</i> , 2020, 215, 31-40.	2.2	0
178	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 136-158.	0.9	15
179	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
180	Genetics of Childhood-onset Schizophrenia 2019 Update. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 157-170.	1.0	21
181	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. <i>Cancer Letters</i> , 2020, 469, 246-255.	3.2	12
182	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51
183	COUP-TFII Knock-down Promotes Proliferation and Invasion in Colorectal Cancer Cells via Activation of Akt Pathway and Up-regulation of FOXC1. <i>Anticancer Research</i> , 2020, 40, 177-190.	0.5	3
184	Interaction between DNA damage response and autophagy in colorectal cancer. <i>Gene</i> , 2020, 730, 144323.	1.0	11
185	Cancer-targeted PEDF-DNA therapy for metastatic colorectal cancer. <i>International Journal of Pharmaceutics</i> , 2020, 576, 118999.	2.6	29
186	BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. <i>Nature Communications</i> , 2020, 11, 19.	5.8	27
187	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 81% of 12 years of follow-up. <i>International Journal of Cancer</i> , 2020, 146, 2019-2026.	2.3	14
188	Colonic Adenocarcinomas Harboring NTRK Fusion Genes. <i>American Journal of Surgical Pathology</i> , 2020, 44, 162-173.	2.1	56
189	<i>Fusobacterium nucleatum</i> Promotes Metastasis in Colorectal Cancer by Activating Autophagy Signaling via the Upregulation of CARD3 Expression. <i>Theranostics</i> , 2020, 10, 323-339.	4.6	115

#	ARTICLE	IF	CITATIONS
190	Precision nutrition to target lipid metabolism alterations in cancer. , 2020, , 291-299.		10
191	Epigenetics of colorectal cancer: biomarker and therapeutic potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 111-130.	8.2	449
192	MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 198.	3.5	10
193	Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status. <i>Cancers</i> , 2020, 12, 2902.	1.7	13
194	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
195	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
196	INHBB Is a Novel Prognostic Biomarker Associated with Cancer-Promoting Pathways in Colorectal Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	24
197	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
198	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 138, 1-10.	1.3	23
199	Spatial domain analysis predicts risk of colorectal cancer recurrence and infers associated tumor microenvironment networks. <i>Nature Communications</i> , 2020, 11, 3515.	5.8	24
200	Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. <i>Journal of Radiation Research</i> , 2020, 61, 766-775.	0.8	17
201	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1135-1147.	0.6	58
202	A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 3250-3261.	2.3	6
203	Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3355.	1.7	29
204	Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 569017.	1.3	21
205	Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. <i>BMC Cancer</i> , 2020, 20, 1149.	1.1	20
206	Deep phenotyping of synovial molecular signatures by integrative systems analysis in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 3420-3431.	0.9	7
207	Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant. <i>Cell Death and Disease</i> , 2020, 11, 1020.	2.7	15

#	ARTICLE	IF	CITATIONS
208	Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	0.9	2
209	Metabolism-Associated Molecular Classification of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 602498.	1.3	16
210	Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis. <i>Cancers</i> , 2020, 12, 2014.	1.7	16
211	Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. <i>Nature Cancer</i> , 2020, 1, 800-810.	5.7	339
212	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	1.4	37
213	Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2193.	1.7	5
214	BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. <i>Oncogene</i> , 2020, 39, 6053-6070.	2.6	19
215	YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. <i>Cancers</i> , 2020, 12, 3160.	1.7	15
216	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568911.	1.3	17
217	In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. <i>Gastroenterology</i> , 2020, 159, 2163-2180.e6.	0.6	83
218	Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 577420.	1.3	107
219	Ribosome Biogenesis Alterations in Colorectal Cancer. <i>Cells</i> , 2020, 9, 2361.	1.8	28
220	AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	48
221	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated " NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
222	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457.	1.7	3
223	Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells. <i>Scientific Reports</i> , 2020, 10, 13988.	1.6	28
224	Organoid in colorectal cancer: progress and challenges. <i>Chinese Medical Journal</i> , 2020, 133, 1971-1977.	0.9	14
225	A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. <i>Cancers</i> , 2020, 12, 2410.	1.7	27

#	ARTICLE	IF	CITATIONS
226	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Targeted Oncology, 2020, 15, 567-577.	1.7	14
228	APC and AXIN2 Are Promising Biomarker Candidates for the Early Detection of Adenomas and Hyperplastic Polyps. Cancer Informatics, 2020, 19, 117693512097238.	0.9	1
229	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Frontiers in Immunology, 2020, 11, 600886.	2.2	43
230	Integrating Tumor Stroma Biomarkers With Clinical Indicators for Colon Cancer Survival Stratification. Frontiers in Medicine, 2020, 7, 584747.	1.2	4
231	Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis. Frontiers in Oncology, 2020, 10, 594098.	1.3	11
232	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Annals of Gastroenterological Surgery, 2020, 4, 635-645.	1.2	5
233	Clinicopathological significance and prognostic implication of CD44 and its splice variants (v3 and v4) in colorectal cancer. Journal of Cellular Biochemistry, 2020, 121, 100-104.	0.4	4
234	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23
235	Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors: 2020 Update. Journal of Clinical Medicine, 2020, 9, 3520.	1.0	16
237	FNDC3B, Targeted by miR-125a-5p and miR-217, Promotes the Proliferation and Invasion of Colorectal Cancer Cells via PI3K/mTOR Signaling. OncoTargets and Therapy, 2020, Volume 13, 3501-3510.	1.0	19
238	Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature Communications, 2020, 11, 2333.	5.8	33
239	Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Frontiers in Immunology, 2020, 11, 1052.	2.2	55
240	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	1.3	12
241	A Novel Method for Cancer Subtyping and Risk Prediction Using Consensus Factor Analysis. Frontiers in Oncology, 2020, 10, 1052.	1.3	13
242	The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication. Frontiers in Cell and Developmental Biology, 2020, 8, 442.	1.8	29
243	Identification of Early Warning Signals at the Critical Transition Point of Colorectal Cancer Based on Dynamic Network Analysis. Frontiers in Bioengineering and Biotechnology, 2020, 8, 530.	2.0	7
244	Development and validation of an individualized gene expression-based signature to predict overall survival in metastatic colorectal cancer. Annals of Translational Medicine, 2020, 8, 96-96.	0.7	6
245	Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, 2020, 5, 22.	7.1	853

#	ARTICLE	IF	CITATIONS
246	Comprehensive transcriptome profiling of Taiwanese colorectal cancer implicates an ethnic basis for pathogenesis. <i>Scientific Reports</i> , 2020, 10, 4526.	1.6	9
247	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. <i>Cancers</i> , 2020, 12, 638.	1.7	52
248	A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. <i>Genome Medicine</i> , 2020, 12, 24.	3.6	34
249	Clinicopathologic characteristics of resectable colorectal cancer with mismatch repair protein defects in Chinese population. <i>Medicine (United States)</i> , 2020, 99, e20554.	0.4	4
250	Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer. <i>Oncolmmunology</i> , 2020, 9, 1773205.	2.1	3
251	Combination of preoperative tumour markers and lymphovascular invasion with TNM staging as a cost and labour efficient subtyping of colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 10238.	1.6	8
252	Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study. <i>Modern Pathology</i> , 2020, 33, 2626-2636.	2.9	17
253	Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAFV600</i> -Wild-Type Colorectal Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 835-846.	1.5	22
254	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2020, 121, 984-989.	0.8	1
255	EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. <i>Scientific Reports</i> , 2020, 10, 3723.	1.6	13
256	DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation. <i>IScience</i> , 2020, 23, 100838.	1.9	4
257	Insights regarding novel biomarkers and the pathogenesis of primary colorectal carcinoma based on bioinformatic analysis. <i>Computational Biology and Chemistry</i> , 2020, 85, 107229.	1.1	14
258	PD-1/PD-L1-dependent immune response in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5461-5475.	2.0	86
259	CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. <i>Molecular Cancer</i> , 2020, 19, 13.	7.9	146
260	Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer. <i>Oncogene</i> , 2020, 39, 2453-2466.	2.6	18
261	The somatic mutation landscape of Chinese Colorectal Cancer. <i>Journal of Cancer</i> , 2020, 11, 1038-1046.	1.2	16
262	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. <i>Cancers</i> , 2020, 12, 330.	1.7	11
263	A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma. <i>Genes</i> , 2020, 11, 155.	1.0	8

#	ARTICLE	IF	CITATIONS
264	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000634.	2.0	20
265	Mapping the spreading routes of lymphatic metastases in human colorectal cancer. <i>Nature Communications</i> , 2020, 11, 1993.	5.8	68
266	Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Frontiers in Pharmacology</i> , 2020, 11, 478.	1.6	22
267	Bioresponsive Nanomedicine: The Next Step of Deadliest Cancers' Theranostics. <i>Frontiers in Chemistry</i> , 2020, 8, 257.	1.8	7
268	Association between local immune cell infiltration, mismatch repair status and systemic inflammatory response in colorectal cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 178.	1.8	17
269	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
270	Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival. <i>Journal of Medical Genetics</i> , 2021, 58, 12-19.	1.5	22
271	Stereotactic ablative radiotherapy for colorectal cancer liver metastasis. <i>Seminars in Cancer Biology</i> , 2021, 71, 21-32.	4.3	14
272	Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. <i>British Journal of Cancer</i> , 2021, 124, 663-670.	2.9	25
273	LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF- β /SMAD2/3 signaling pathway. <i>Cell Death and Differentiation</i> , 2021, 28, 219-232.	5.0	99
274	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. <i>Gut</i> , 2021, 70, 544-554.	6.1	148
275	Mutations and mechanisms of WNT pathway tumour suppressors in cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 5-21.	12.8	235
276	Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population. <i>Developmental Cell</i> , 2021, 56, 95-110.e10.	3.1	50
277	Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155 . <i>International Journal of Cancer</i> , 2021, 148, 1948-1963.	2.3	11
278	Novel Genetic and Epigenetic Biomarkers of Prognostic and Predictive Significance in Stage II/III Colorectal Cancer. <i>Molecular Therapy</i> , 2021, 29, 587-596.	3.7	52
279	Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1. <i>Clinical Colorectal Cancer</i> , 2021, 20, 84-95.e8.	1.0	15
280	Computational Analysis of Phosphoproteomics Data in Multi-omics Cancer Studies. <i>Proteomics</i> , 2021, 21, e1900312.	1.3	20
281	Unraveling the genomic landscape of colorectal cancer through mutational signatures. <i>Advances in Cancer Research</i> , 2021, 151, 385-424.	1.9	14

#	ARTICLE	IF	CITATIONS
282	Epigenetics of Aging and Aging-Associated Diseases. International Journal of Molecular Sciences, 2021, 22, 401.	1.8	110
283	Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. British Journal of Surgery, 2021, 108, 1417-1425.	0.1	57
284	A template to quantify the location and density of CD3 ⁺ and CD8 ⁺ tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment. Cancer Immunology, Immunotherapy, 2021, 70, 2049-2057.	2.0	7
286	Multi-Disease Prediction Based on Deep Learning: A Survey. CMES - Computer Modeling in Engineering and Sciences, 2021, 128, 489-522.	0.8	123
287	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers, 2021, 13, 137.	1.7	46
288	Gut Microbiome and Cancer. The Microbiomes of Humans, Animals, Plants, and the Environment, 2021, , 93-168.	0.2	0
290	HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cellular and Molecular Immunology, 2021, 18, 556-565.	4.8	55
291	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. OncoImmunology, 2021, 10, 1940674.	2.1	11
292	Effective Cancer Subtype and Stage Prediction via Dropfeature-DNNs. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 107-120.	1.9	1
293	Anti-Cancer Biosurfactants. Environmental and Microbial Biotechnology, 2021, , 159-196.	0.4	1
294	Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 555-565.	1.1	3
295	Bioresponsive nano-theranostic approaches for cancer targeting. , 2021, , 409-413.		0
296	Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. Clinical Cancer Research, 2021, 27, 2159-2167.	3.2	9
297	Opportunities and Perspectives of NGS Applications in Cancer Research. Learning Materials in Biosciences, 2021, , 17-38.	0.2	0
298	Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer. Oncogene, 2021, 40, 2130-2145.	2.6	15
299	Understanding cell-cell communication and signaling in the colorectal cancer microenvironment. Clinical and Translational Medicine, 2021, 11, e308.	1.7	52
300	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT), Tj ETQq0 0 0 rgB.7/Overlock 10 Tf 50	2.7	10
301	Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment. Nature Communications, 2021, 12, 759.	5.8	61

#	ARTICLE	IF	CITATIONS
302	HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome. <i>Npj Genomic Medicine</i> , 2021, 6, 13.	1.7	17
303	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. <i>Diagnostics</i> , 2021, 11, 339.	1.3	46
304	Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/ β -Catenin Signaling through Enhanced Smad4 α -LEF1 Binding. <i>Molecular Cancer Research</i> , 2021, 19, 823-833.	1.5	4
305	Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2067.	1.8	14
306	Prognosis model of colorectal cancer patients based on NOTCH3, KMT2C, and CREBBP mutations. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 79-88.	0.6	8
308	Protective effect of notoginsenoside and tanshinone IIA on inflammation-related colorectal cancer mice and the inhibition effect on COX-2 expression. <i>Digital Chinese Medicine</i> , 2021, 4, 54-63.	0.5	4
309	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
310	Molecular Oncology in Management of Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 169-180.	0.3	0
311	Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. <i>Biomedical Journal</i> , 2021, , .	1.4	2
312	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	1.8	47
313	Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 643375.	1.3	2
314	Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2021, 14, 232-238.	0.3	12
315	Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers. <i>Cancers</i> , 2021, 13, 1328.	1.7	7
316	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
317	BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3811.	1.8	3
318	Multilevel prioritization of gene regulators associated with consensus molecular subtypes of colorectal cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	4
319	PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification. <i>Cancers</i> , 2021, 13, 1943.	1.7	13
320	Outcomes of young patients diagnosed with locally advanced rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 592-601.	0.6	2

#	ARTICLE	IF	CITATIONS
321	Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy. <i>Current Medicinal Chemistry</i> , 2021, 28, 963-985.	1.2	14
322	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , 2022, 84, 199-213.	4.3	35
323	The clinical relevance of gene expression based prognostic signatures in colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188513.	3.3	56
324	Genomics and Cancer Disparities: The Justice and Power of Inclusion. <i>Cancer Discovery</i> , 2021, 11, 805-809.	7.7	11
325	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. <i>Cancer Discovery</i> , 2021, 11, 1644-1660.	7.7	11
326	Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A IDO1. <i>Frontiers in Oncology</i> , 2021, 11, 632430.	1.3	32
327	Comprehensive Analysis of Prognostic and Genetic Signatures for General Transcription Factor III (GTF3) in Clinical Colorectal Cancer Patients Using Bioinformatics Approaches. <i>Current Issues in Molecular Biology</i> , 2021, 43, 2-20.	1.0	20
328	The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. <i>British Journal of Cancer</i> , 2021, 125, 240-246.	2.9	8
329	Host IL11 Signaling Suppresses CD4+ T cell-Mediated Antitumor Responses to Colon Cancer in Mice. <i>Cancer Immunology Research</i> , 2021, 9, 735-747.	1.6	23
330	Precision oncology in metastatic colorectal cancer – from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
331	Claudin-Low Breast Cancer Inflammatory Signatures Support Polarization of M1-Like Macrophages with Protumoral Activity. <i>Cancers</i> , 2021, 13, 2248.	1.7	7
332	CBF β promotes colorectal cancer progression through transcriptionally activating OPN, FAM129A, and UPP1 in a RUNX2-dependent manner. <i>Cell Death and Differentiation</i> , 2021, 28, 3176-3192.	5.0	12
333	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021, 1, 311-325.	0.1	0
334	Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2021, 13, 2290.	1.7	17
335	The miR-106b/NR2F2-AS1/PLEKHO2 Axis Regulates Migration and Invasion of Colorectal Cancer through the MAPK Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5877.	1.8	4
336	Identification of Hypertension Subgroups through Topological Analysis of Symptom-Based Patient Similarity. <i>Chinese Journal of Integrative Medicine</i> , 2021, 27, 656-665.	0.7	5
337	A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century. <i>Current Medicinal Chemistry</i> , 2021, 28, 2657-2696.	1.2	19
338	Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5019.	1.8	8

#	ARTICLE	IF	CITATIONS
340	Organoids and Colorectal Cancer. <i>Cancers</i> , 2021, 13, 2657.	1.7	26
341	Identifying Novel Actionable Targets in Colon Cancer. <i>Biomedicines</i> , 2021, 9, 579.	1.4	13
342	Comprehensive Analysis of Differentially Expressed Long Noncoding RNA-mRNA in the Adenoma-Carcinoma Sequence of DNA Mismatch Repair Proficient Colon Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	0
343	Machine Learning Model for Predicting Postoperative Survival of Patients with Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 517-524.	1.3	9
344	Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6940.	1.8	19
345	HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 993-1002.	1.2	10
346	Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 3280.	1.7	5
347	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	1.1	0
348	Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. <i>Oncogene</i> , 2021, 40, 4352-4367.	2.6	17
349	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1420-1430.	1.0	3
350	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 185.	3.5	20
351	Molecular genetic classification of colorectal cancer subtypes: current state of the problem. <i>South Russian Journal of Cancer</i> , 2021, 2, 50-56.	0.1	7
352	CDK15 promotes colorectal cancer progression via phosphorylating PAK4 and regulating β -catenin/MEK-ERK signaling pathway. <i>Cell Death and Differentiation</i> , 2022, 29, 14-27.	5.0	26
353	CTSE Overexpression Is an Adverse Prognostic Factor for Survival among Rectal Cancer Patients Receiving CCRT. <i>Life</i> , 2021, 11, 646.	1.1	3
354	BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705060.	1.8	20
355	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. <i>Npj Genomic Medicine</i> , 2021, 6, 59.	1.7	29
356	Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 592-607.	0.6	81
357	Core Circadian Clock Proteins as Biomarkers of Progression in Colorectal Cancer. <i>Biomedicines</i> , 2021, 9, 967.	1.4	5

#	ARTICLE	IF	CITATIONS
358	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1197-1206.	2.1	2
359	Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 689466.	1.6	5
360	Molecular Subtypes of Oral Squamous Cell Carcinoma Based on Immunosuppression Genes Using a Deep Learning Approach. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 687245.	1.8	7
361	MicroRNAs in blood act as biomarkers of colorectal cancer and indicate potential therapeutic targets. <i>Molecular Oncology</i> , 2021, 15, 2480-2490.	2.1	5
362	Luteolin-Loading Her-2 Nanospheres Enhances Targeting and Therapeutic Effects of Breast Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1545-1553.	0.5	3
363	In situ functional cell phenotyping reveals microdomain networks in colorectal cancer recurrence. <i>Cell Reports Methods</i> , 2021, 1, 100072.	1.4	3
364	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. <i>Scientific Reports</i> , 2021, 11, 19432.	1.6	6
365	Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. <i>Gut</i> , 2022, 71, 1340-1349.	6.1	17
366	Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4923.	1.7	19
367	Heparanase (HPSE) Associates with the Tumor Immune Microenvironment in Colorectal Cancer. <i>Processes</i> , 2021, 9, 1605.	1.3	2
368	circTADA2A Retards the Progression of Colorectal Cancer via Regulating miR-1229/BCL2L10 Signal Axis. <i>Cancer Management and Research</i> , 2021, Volume 13, 6811-6821.	0.9	2
369	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021, 13, 143.	3.6	10
370	Personalised Medicine for Colorectal Cancer Using Mechanism-Based Machine Learning Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9970.	1.8	7
371	Remodeling tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2057-2073.	5.7	24
372	LncRNA FTX promotes the malignant progression of colorectal cancer by regulating the miR-214-5p/JAG1 axis. <i>Annals of Translational Medicine</i> , 2021, 9, 1369-1369.	0.7	11
373	Great future or greedy venture: Precision medicine needs philosophy. <i>Health Science Reports</i> , 2021, 4, e376.	0.6	1
374	Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer. <i>Biomaterials</i> , 2021, 277, 121105.	5.7	15
375	Selective in vitro cytotoxicity effect of <i>Drimys calcarata</i> bulb extracts against p53 mutant HT-29 and p53 wild-type Caco-2 colorectal cancer cells through STAT5B regulation. <i>Toxicology Reports</i> , 2021, 8, 1265-1279.	1.6	11

#	ARTICLE	IF	CITATIONS
376	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
377	Two immune-enhanced molecular subtypes differ in inflammation, immune checkpoints, mutations, and prognostic outcome in stage II colonic carcinoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22703.	1.4	1
378	Genetic Instability Markers in Cancer. <i>Methods in Molecular Biology</i> , 2020, 2055, 133-154.	0.4	2
379	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. <i>Nature Genetics</i> , 2020, 52, 594-603.	9.4	380
384	Disease subtyping using community detection from consensus networks. , 2020, , .		3
385	EHF promotes colorectal carcinoma progression by activating TGF β 1 transcription and canonical TGF β 2 signaling. <i>Cancer Science</i> , 2020, 111, 2310-2324.	1.7	16
386	<i>F. nucleatum</i> targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. <i>Gut</i> , 2021, 70, 2123-2137.	6.1	136
387	<i>NAMPT</i> Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. <i>Clinical Cancer Research</i> , 2018, 24, 1202-1215.	3.2	106
388	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	22
389	Smoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1940-1949.	0.2	95
390	Depressed Colorectal Cancer: A New Paradigm in Early Colorectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00269.	1.3	7
391	A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment. <i>Aging</i> , 2019, 11, 8587-8603.	1.4	22
392	Lycorine induces autophagy-associated apoptosis by targeting MEK2 and enhances vemurafenib activity in colorectal cancer. <i>Aging</i> , 2020, 12, 138-155.	1.4	18
393	Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer. <i>Aging</i> , 2020, 12, 26095-26120.	1.4	35
394	Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. <i>Oncotarget</i> , 2017, 8, 87837-87847.	0.8	49
395	Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method. <i>Oncotarget</i> , 2017, 8, 92926-92942.	0.8	6
396	Immunological landscape of consensus clusters in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 105299-105311.	0.8	55
397	SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. <i>Oncotarget</i> , 2018, 9, 2128-2139.	0.8	52

#	ARTICLE	IF	CITATIONS
398	MicroRNA-873 inhibits colorectal cancer metastasis by targeting ELK1 and STRN4. <i>Oncotarget</i> , 2019, 10, 4192-4204.	0.8	15
399	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
400	Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision. <i>Radiology and Oncology</i> , 2020, 54, 272-277.	0.6	22
401	Mutation detection and molecular targeted tumor therapies. <i>STEMedicine</i> , 2020, 1, e11.	0.5	31
402	CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 4738-4749.	1.4	99
403	Predicting systemic spread in early colorectal cancer: Can we do better?. <i>World Journal of Gastroenterology</i> , 2019, 25, 2887-2897.	1.4	19
404	Impairment of DYRK2 by DNMT1-mediated transcription augments carcinogenesis in human colorectal cancer. <i>International Journal of Oncology</i> , 2020, 56, 1529-1539.	1.4	10
405	Identification of key genes involved in the development and progression of early-onset colorectal cancer by co-expression network analysis. <i>Oncology Letters</i> , 2020, 19, 177-186.	0.8	46
406	Mechanism of miR-98 inhibiting tumor proliferation and invasion by targeting IGF1R in diabetic patients combined with colon cancer. <i>Oncology Letters</i> , 2020, 20, 1719-1726.	0.8	7
407	<i>Fusobacterium nucleatum</i> promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. <i>Gut Microbes</i> , 2021, 13, 1980347.	4.3	90
408	A Novel Cancer Stemness-Related Signature for Predicting Prognosis in Patients with Colon Adenocarcinoma. <i>Stem Cells International</i> , 2021, 2021, 1-23.	1.2	16
409	LIN28 promotes tumorigenesis in colorectal cancer but is not associated with metastatic spread. <i>Pathology Research and Practice</i> , 2021, 228, 153669.	1.0	4
410	Tumor-suppressive function of EZH2 is through inhibiting glutaminase. <i>Cell Death and Disease</i> , 2021, 12, 975.	2.7	6
411	The Intratumor Microbiota Signatures Associate With Subtype, Tumor Stage, and Survival Status of Esophageal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 754788.	1.3	15
412	Impact of the ileal microbiota on colon cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 955-966.	4.3	11
413	Recent novel tumor gatekeepers and potential therapeutic approaches (2017). <i>Tropical Journal of Pharmaceutical Research</i> , 2017, 16, 2545-2553.	0.2	0
415	Colorectal Cancer Prevention. , 2019, , 473-509.		1
416	Identification of the Altered Proteins Related to Colon Carcinogenesis by iTRAQ-based Quantitative Proteomic Analysis. <i>Current Proteomics</i> , 2019, 16, 297-306.	0.1	0

#	ARTICLE	IF	CITATIONS
418	Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-154.	0.9	7
419	Role of circular RNAs in digestive system malignancies. World Chinese Journal of Digestology, 2020, 28, 417-427.	0.0	0
420	Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015â€”2019: an observational retrospective database analysis. BMJ Open, 2021, 11, e046166.	0.8	2
421	Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology, 2022, 162, 715-730.e3.	0.6	193
422	Differential Expression of the Sphingolipid Pathway Is Associated with Sensitivity to the PP2A Activator FTY720 in Colorectal Cancer Cell Lines. Journal of Clinical Medicine, 2021, 10, 4999.	1.0	1
423	APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes. Cancers, 2021, 13, 5394.	1.7	7
424	Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC). Annals of Surgical Oncology, 2022, 29, 1939-1951.	0.7	10
425	Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival. Journal of Surgical Research, 2022, 270, 169-177.	0.8	4
427	The Unreasonable Effectiveness of Inverse Reinforcement Learning in Advancing Cancer Research. Proceedings of the AAAI Conference on Artificial Intelligence, 2020, 34, 437-445.	3.6	5
428	ASPP2 ¹ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Frontiers in Molecular Biosciences, 2021, 8, 727203.	1.6	2
429	KMT9 Controls Stemness and Growth of Colorectal Cancer. Cancer Research, 2022, 82, 210-220.	0.4	11
433	Analysis of DNA methylation-driven genes for predicting the prognosis of patients with colorectal cancer. Aging, 2020, 12, 22814-22839.	1.4	3
434	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clinical Advances in Hematology and Oncology, 2018, 16, 735-745.	0.3	59
435	Long non-coding RNA SNHG20 promotes colorectal cancer cell proliferation, migration and invasion via miR-495/STAT3 axis. Molecular Medicine Reports, 2021, 23, .	1.1	4
436	Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer detection. American Journal of Translational Research (discontinued), 2020, 12, 7395-7403.	0.0	9
437	The Unreasonable Effectiveness of Inverse Reinforcement Learning in Advancing Cancer Research. Proceedings of the AAAI Conference on Artificial Intelligence, 2020, 34, 437-445.	3.6	0
438	Translational epigenetics in precision medicine of colorectal cancer. , 2022, , 19-41.		0
439	Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach. World Journal of Clinical Oncology, 2021, 12, 1000-1008.	0.9	24

#	ARTICLE	IF	CITATIONS
440	Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5824.	1.7	4
441	Treatment of HT29 Human Colorectal Cancer Cell Line with Nanocarrier-Encapsulated Camptothecin Reveals Histone Modifier Genes in the Wnt Signaling Pathway as Important Molecular Cues for Colon Cancer Targeting. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12286.	1.8	4
442	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 764618.	1.3	17
443	A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma. <i>Cancers</i> , 2021, 13, 5909.	1.7	5
444	TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 171-179.	0.8	33
445	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24141.	0.9	12
446	Long non-coding RNA SNHG20 promotes colorectal cancer cell proliferation, migration and invasion via miR-495/STAT3 axis. <i>Molecular Medicine Reports</i> , 2020, 23, 1-1.	1.1	6
447	Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-Derived Organoids. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
448	The prognostic role of miR-31 in colorectal cancer: the results of a meta-analysis of 4720 patients. <i>Epigenomics</i> , 2022, 14, 101-112.	1.0	4
449	Identification of a prognostic signature in colorectal cancer using combinatorial algorithm-driven analysis. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	1.3	1
450	Enforced dual-specificity tyrosine-regulated kinase 2 expression by adenovirus-mediated gene transfer inhibits tumor growth and metastasis of colorectal cancer. <i>Cancer Science</i> , 2022, 113, 960-970.	1.7	4
451	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
452	Rewired lipid metabolism as an actionable vulnerability of aggressive colorectal carcinoma. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2024051.	0.3	3
453	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. <i>Journal of Personalized Medicine</i> , 2022, 12, 128.	1.1	6
454	Predictive omic-biomarkers of drug response: Colorectal cancer as a model. , 2022, , 199-240.		2
455	A glycolysis-related two-gene risk model that can effectively predict the prognosis of patients with rectal cancer. <i>Human Genomics</i> , 2022, 16, 5.	1.4	7
456	Liquidambaric acid inhibits Wnt/ β -catenin signaling and colon cancer via targeting TNF receptor-associated factor 2. <i>Cell Reports</i> , 2022, 38, 110319.	2.9	20
457	Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 172, 16-30.	2.0	4

#	ARTICLE	IF	CITATIONS
458	TSG-6 promotes Cancer Cell aggressiveness in a CD44-Dependent Manner and Reprograms Normal Fibroblasts to create a Pro-metastatic Microenvironment in Colorectal Cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 1677-1694.	2.6	17
459	Hypoxia Tumor Microenvironment Activates GLI2 through HIF-1 α and TGF- β 2 to Promote Chemotherapy Resistance of Colorectal Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	5
460	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. <i>Nature Cancer</i> , 2022, 3, 219-231.	5.7	24
461	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. <i>Nature</i> , 2022, 601, 85-91.	13.7	117
462	Long Non-Coding RNA <i>EVADR</i> ; Induced by <i>Fusobacterium nucleatum</i> ; Infection Promotes Colorectal Cancer Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
463	Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 130-144.	1.0	0
464	A Hybrid Machine Learning and Network Analysis Approach Reveals Two Parkinson's Disease Subtypes from 115 RNA-Seq Post-Mortem Brain Samples. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2557.	1.8	3
465	Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy. <i>Journal of Surgical Oncology</i> , 2022, 125, 1002-1012.	0.8	4
466	Development of dentition: From initiation to occlusion and related diseases. <i>Journal of Oral Biosciences</i> , 2022, 64, 159-164.	0.8	6
467	Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 60.	7.1	31
468	Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact. <i>Cancers</i> , 2022, 14, 928.	1.7	7
469	Molecular Endoscopy for the Diagnosis and Therapeutic Monitoring of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 835256.	1.3	1
470	Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 801484.	1.1	8
471	The putative oncogenic role of <i>WDC1</i> in colorectal cancer. <i>Carcinogenesis</i> , 2022, , .	1.3	2
472	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 848327.	2.2	11
473	In Vitro Characterization of ¹⁷⁷ Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 849338.	1.3	3
474	Polymerase Epsilon-Associated Ultramutagenesis in Cancer. <i>Cancers</i> , 2022, 14, 1467.	1.7	9
475	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 2110-2117.	3.2	30

#	ARTICLE	IF	CITATIONS
476	The impact of low serum cholinesterase levels on survival in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2022, 37, 869-877.	1.0	10
478	Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. <i>Nature Communications</i> , 2022, 13, 1618.	5.8	23
479	Downregulation of B3GNT6 is a predictor of poor outcomes in patients with colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, 110.	0.8	1
480	Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients. <i>Iranian Journal of Pathology</i> , 2022, 17, 150-158.	0.2	1
481	Mucin phenotypes and clinicopathological features of colorectal adenocarcinomas: Correlation with colorectal adenocarcinoma with enteroblastic differentiation. <i>Pathology Research and Practice</i> , 2022, 232, 153840.	1.0	2
482	DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188722.	3.3	45
483	Genotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer. <i>Annals of Coloproctology</i> , 2021, 37, 368-381.	0.5	14
484	High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. <i>Anticancer Research</i> , 2022, 42, 407-417.	0.5	1
485	The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer at high risk of metastatic progression. <i>Clinical and Translational Oncology</i> , 2022, 24, 1157-1167.	1.2	2
486	Smell Detection Agent Optimisation Framework and Systems Biology Approach to Detect Dys-Regulated Subnetwork in Cancer Data. <i>Biomolecules</i> , 2022, 12, 37.	1.8	0
487	Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 747-756.	1.1	1
488	Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology. <i>Clinical and Molecular Hepatology</i> , 2022, , .	4.5	10
516	Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 514-523.	2.9	14
517	Protruding structures with high expression of LGR5 are formed during regrowth phase after chemo-treatment in xenograft model of colorectal adenocarcinoma. <i>Histology and Histopathology</i> , 2021, , 18374.	0.5	0
518	Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5-FU by promoting the SDF-1/CXCR4/Akt axis. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	6
519	Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-8.	0.8	2
521	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 279-298.	1.8	11
522	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26

#	ARTICLE	IF	CITATIONS
523	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
524	Negative Ultraselection of Patients With <i>RAS</i> / <i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2200037.	1.5	11
525	Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
526	Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
527	Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis. <i>PLoS ONE</i> , 2022, 17, e0268436.	1.1	3
528	Transcriptome of sessile serrated adenoma/polyps is associated with high colorectal cancer and decreased expression of <i>CDX2</i> . <i>Cancer Medicine</i> , 2022, 11, 5066-5078.	1.3	5
530	Long intergenic non-protein-coding RNA 467 promotes tumor progression and angiogenesis via the microRNA-128-3p/vascular endothelial growth factor C axis in colorectal cancer. <i>Bioengineered</i> , 2022, 13, 12392-12408.	1.4	1
531	Insight on <i>BRAF</i> ^{V600E} mutated colorectal cancer immune microenvironment. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1213-1215.	0.8	1
532	Oncogenic Signalling of <i>PEAK2</i> Pseudokinase in Colon Cancer. <i>Cancers</i> , 2022, 14, 2981.	1.7	1
533	The Therapeutic Role of <i>PNU-74654</i> in Hepatocellular Carcinoma May Involve Suppression of <i>NF-ÎB</i> Signaling. <i>Medicina (Lithuania)</i> , 2022, 58, 798.	0.8	3
534	Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
535	Repurposing of ingenol mebutate for treating human colorectal cancer by targeting <i>S100</i> calcium-binding protein A4 (<i>S100A4</i>). <i>Toxicology and Applied Pharmacology</i> , 2022, 449, 116134.	1.3	3
536	Research Progress on the Difference between Left and Right Colon Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 5999-6006.	0.0	0
537	Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. <i>Nature Genetics</i> , 2022, 54, 963-975.	9.4	106
538	Immunotherapy for Colorectal Cancer in the Era of Precision Medicine. , 0, , .		0
539	Circular RNA <i>circDLR</i> facilitates cancer progression by altering the <i>miR-30a-3p/SOAT1</i> axis in colorectal cancer. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	7
540	<i>CLK2</i> Expression Is Associated with the Progression of Colorectal Cancer and Is a Prognostic Biomarker. <i>BioMed Research International</i> , 2022, 2022, 1-11.	0.9	3
541	Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing. <i>British Journal of Cancer</i> , 2022, 127, 1304-1311.	2.9	8

#	ARTICLE	IF	CITATIONS
543	A Generalized Integration Approach to Association Analysis with Multi-category Outcome: An Application to a Tumor Sequencing Study of Colorectal Cancer and Smoking. <i>Journal of the American Statistical Association</i> , 2023, 118, 29-42.	1.8	0
544	Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3874-3889.	3.2	13
545	Metabolic balance in colorectal cancer is maintained by optimal Wnt signaling levels. <i>Molecular Systems Biology</i> , 2022, 18, .	3.2	3
546	Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
547	Utilising Proteomics and Organoid Cultures for Predicting Treatment Response in Colorectal Cancer. , 0, , .		0
548	Colon mucus in colorectal neoplasia and beyond. <i>World Journal of Gastroenterology</i> , 2022, 28, 4475-4492.	1.4	2
549	Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 4012.	1.7	10
550	Sequential acid/reduction response of triblock copolymeric nanomicelles to release camptothecin and toll-like receptor 7/8 agonist for orchestrated chemoimmunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	2
552	CYCLODEXTRIN BASED ARSENAL FOR ANTI " TUMOUR TREATMENT. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2022, , .	1.2	0
553	The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5065-5075.	1.9	0
554	Identification of Tissue Types and Gene Mutations From Histopathology Images for Advancing Colorectal Cancer Biology. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2022, 3, 115-123.	1.7	5
555	Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
556	Crosstalk of Oxidative Phosphorylation-Related Subtypes, Establishment of a Prognostic Signature and Immune Infiltration Characteristics in Colorectal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4503.	1.7	3
557	Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
558	Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	41
559	Popular deep learning algorithms for disease prediction: a review. <i>Cluster Computing</i> , 2023, 26, 1231-1251.	3.5	18
560	DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
561	Emergent impact of lifestyle on tumor progression and response to therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , ix-xvii.	1.6	0

#	ARTICLE	IF	CITATIONS
562	Identifying Tissue- and Cohort-Specific RNA Regulatory Modules in Cancer Cells Using Multitask Learning. <i>Cancers</i> , 2022, 14, 4939.	1.7	0
563	Neuraminidase-1: A Sialidase Involved in the Development of Cancers and Metabolic Diseases. <i>Cancers</i> , 2022, 14, 4868.	1.7	7
564	Decoding the colorectal cancer ecosystem emphasizes the cooperative role of cancer cells, TAMs and CAFsin tumor progression. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
565	High-fat diet induced cyclophilin B enhances STAT3/lncRNA-PVT1 feedforward loop and promotes growth and metastasis in colorectal cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
566	Pseudogenes and the associated ceRNA network as potential prognostic biomarkers for colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
567	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. <i>Cancers</i> , 2022, 14, 4834.	1.7	0
568	A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	9
569	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
570	Association between chili pepper consumption and risk of gastrointestinal-tract cancers: A meta-analysis. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	2
571	Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, <scp>EMT</scp> nor metastatic spread in colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 0, , .	1.3	0
572	EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3). <i>Cancers</i> , 2022, 14, 5596.	1.7	0
573	Optimization of deep learning models for the prediction of gene mutations using unsupervised clustering. <i>Journal of Pathology: Clinical Research</i> , 2023, 9, 3-17.	1.3	6
574	Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211383.	1.4	4
575	Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	3
576	Predictive biomarkers of colon cancer immunotherapy: Present and future. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
578	m6A-modified circFNDC3B inhibits colorectal cancer stemness and metastasis via RNF41-dependent ASB6 degradation. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
579	ACY1 Downregulation Enhances the Radiosensitivity of Cetuximab-Resistant Colorectal Cancer by Inactivating the Wnt/ β -Catenin Signaling Pathway. <i>Cancers</i> , 2022, 14, 5704.	1.7	0
580	Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3

#	ARTICLE	IF	CITATIONS
581	Circ_RNF13 Regulates the Stemness and Chemosensitivity of Colorectal Cancer by Transcriptional Regulation of DDX27 Mediated by TRIM24 Stabilization. <i>Cancers</i> , 2022, 14, 6218.	1.7	1
582	Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. <i>Cancer Cell</i> , 2023, 41, 252-271.e9.	7.7	9
583	Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer. <i>Cancers</i> , 2022, 14, 6131.	1.7	9
584	Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	0
586	Circ_ERBB2 knockdown sensitized colorectal cancer cells to 5-FU via miR-181a-5p/PTEN/Akt pathway. <i>Journal of Biochemical and Molecular Toxicology</i> , 0, , .	1.4	0
587	Multi-Omics Data Analysis for Cancer Research: Colorectal Cancer, Liver Cancer and Lung Cancer. <i>Translational Bioinformatics</i> , 2023, , 77-99.	0.0	0
588	MetaFunc: Taxonomic and Functional Analyses of High Throughput Sequencing for Microbiomes. <i>Gut Microbiome</i> , 0, , 1-41.	0.8	2
589	Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic Signatures. <i>Cells</i> , 2023, 12, 266.	1.8	0
590	Low expression of the dynamic network markers FOS/JUN in pre-deteriorated epithelial cells is associated with the progression of colorectal adenoma to carcinoma. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
591	Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2288.	1.8	5
592	Refining empiric subgroups of pediatric sepsis using machine-learning techniques on observational data. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	7
593	Therapeutic landscape and future direction of metastatic colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 306-322.	8.2	33
595	A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities. <i>Cancers</i> , 2023, 15, 1104.	1.7	1
596	Determinants of Lymph Node Yield and Involvement in Resectable Colon Cancer: A Study of Anatomical, Pathological, and Fresh, Nonfixed Specimen Dissection. <i>Indian Journal of Surgery</i> , 2023, 85, 1177-1183.	0.2	1
597	m6A-related lncRNA-based immune infiltration characteristic analysis and prognostic model for colonic adenocarcinoma. <i>Hereditas</i> , 2023, 160, .	0.5	0
598	Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2299-2309.	3.2	3
599	Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance. <i>Gene</i> , 2023, 864, 147323.	1.0	1
600	Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2023, 15, 2288.	1.7	2

#	ARTICLE	IF	CITATIONS
601	Fistula-Associated Anal Adenocarcinoma: A 20-Year Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2023, 30, 3517-3527.	0.7	2
602	Association of inflammatory bowel disease in first-degree relatives with risk of colorectal cancer: A nationwide case-control study in Sweden. <i>International Journal of Cancer</i> , 2023, 152, 2303-2313.	2.3	1
603	The Efficacy and Mechanism of Qinghua Jianpi Recipe in Inhibiting Canceration of Colorectal Adenoma Based on Inflammatory Cancer Transformation. <i>Journal of Immunology Research</i> , 2023, 2023, 1-19.	0.9	0
604	The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells. <i>Journal of Fluorescence</i> , 2023, 33, 1227-1236.	1.3	2
606	MicroRNA 483 overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. <i>Molecular Oncology</i> , 2023, 17, 1280-1301.	2.1	1
607	KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China. <i>Medicine (United States)</i> , 2023, 102, e33115.	0.4	0
608	Up-regulated Circular RNAs in Colorectal Cancer: New Entities for Therapy and Tools for Identification of Therapeutic Targets. <i>Cancer Genomics and Proteomics</i> , 2023, 20, 132-153.	1.0	0
609	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
610	C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis. <i>Oncogene</i> , 2023, 42, 1333-1346.	2.6	2
611	Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. <i>PLoS ONE</i> , 2023, 18, e0281063.	1.1	2
612	Tumor-suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer. <i>IScience</i> , 2023, 26, 106478.	1.9	0
613	Molecular genetics of early-onset colorectal cancer. <i>World Journal of Biological Chemistry</i> , 0, 14, 13-27.	1.7	6
614	An immunometabolism subtyping system identifies S100A9+ macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. <i>Cell Reports Medicine</i> , 2023, 4, 100987.	3.3	5
615	Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
616	Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancer. <i>Journal of Pathology</i> , 2023, 260, 261-275.	2.1	1
617	Impact of Molecular Status on Metastasectomy of Colorectal Cancer Liver Metastases. <i>Clinics in Colon and Rectal Surgery</i> , 0, , .	0.5	0
618	Weight Loss During Neoadjuvant Therapy Is Associated With Poor Response Among the Patients With Gastrointestinal Cancer: A Propensity Score Matching Analysis. <i>Cancer Control</i> , 2023, 30, .	0.7	0
623	Cancers digestifs. , 2023, , 199-205.		0

#	ARTICLE	IF	CITATIONS
630	Molecular pathology of colorectal cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 116-121.	0.3	0
653	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	2.1	3
660	Translating Molecular Subtypes into Clinical Practice: Precision Medicine in Gastric Cancer. , 0, , .		0
673	Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer. AAPS PharmSciTech, 2024, 25, .	1.5	0
674	Omics-based molecular classifications empowering in precision oncology. Cellular Oncology (Dordrecht), 0, , .	2.1	0
681	Advancements in Precision Medicine. Advances in Bioinformatics and Biomedical Engineering Book Series, 2024, , 310-326.	0.2	0
682	Darmkrebs. , 2024, , 335-354.		0